靶向PI3K/AKT/mTOR信号通路治疗急性T淋巴细胞白血病的研究进展

doi:10.11904/j.issn.1002-3070.2019.05.013

摘要/Abstract

摘要： 急性T淋巴细胞白血病(T-ALL)是来源于胸腺T细胞祖细胞的具有强侵袭性和异质性的血液系统恶性肿瘤。T-ALL约占儿童急性淋巴细胞白血病(ALL)的15%,在成人ALL中的比例约为25%。强化化疗方案的应用使儿童T-ALL患者预后显著提高,但成人及复发耐药T-ALL患者的预后仍较差。研制新型靶向药物特异性阻断T-ALL细胞内生存及耐药相关的异常激活信号通路近年来被认为是治疗成人及复发难治T-ALL患者的新策略。PI3K/AKT/mTOR通路是T-ALL细胞内异常激活信号通路中具有代表性的一条。目前靶向该通路的多种小分子抑制剂已被成功研制,并在治疗T-ALL的研究中取得良好效果。PI3K/AKT/mTOR通路相关抑制剂较传统化疗药物具有更高的特异性和更低的毒副作用,且诸多研究表明其与低剂量化疗药物或其他靶向药物联合治疗T-ALL能发挥协同效应。本综述将总结近年来在PI3K/AKT/mTOR通路与T-ALL相关领域的研究成果,并对基于靶向该通路治疗T-ALL的研究进展一并阐述。

关键词: T-ALL, PI3K/AKT/mTOR, 生物靶向疗法, 肿瘤耐药

Abstract: Acute T lymphoblastic leukemia(T-ALL)is a highly invasive and heterogeneous hematological malignancy derived from thymic T cell progenitor cells.T-ALL accounts for approximately 15% of childhood acute lymphoblastic leukemia(ALL)and approximately 25% of adult ALL.The use of intensive chemotherapy regimens has significantly improved the prognosis of children with T-ALL,but the prognosis of adult and relapsed T-ALL patients remains poor.The development of novel targeted drugs specifically blocking T-ALL cell survival and drug-related abnormal activation signaling pathways has been considered as a new strategy for the treatment of adult and relapsed refractory T-ALL patients in recent years.The phosphatidylinositol 3-kinase(PI3K)/AKT/mammalian target of rapamycin(mTOR)pathway is a representative of the abnormal activation signaling pathways in T-ALL cells.A variety of small molecule inhibitors targeting this pathway has been successfully developed and has achieved good results in the treatment of T-ALL.PI3K/AKT/mTOR pathway-related inhibitors have higher specificity and lower toxicity than traditional chemotherapeutic drugs,and many studies have shown that they can exert synergistic effects with low-dose chemotherapeutic drugs or other targeted drugs in the treatment of T-ALL.This review will summarize recent research results in the field of PI3K/AKT/mTOR pathway and T-ALL,and elaborate the research progress of T-ALL based on targeting this pathway.

Key words: T-ALL, PI3K/AKT/mTOR, Targeted therapy, Drug resistance

中图分类号:

R551.3

黄显博, 史庭 , 叶琇锦. 靶向PI3K/AKT/mTOR信号通路治疗急性T淋巴细胞白血病的研究进展[J]. 实用肿瘤学杂志, 2019, 33(5): 451-455.

HUANG Xianbo, SHI Ting, YE Xiujin. Progress in the treatment of acute T lymphoblastic leukemia by targeting PI3K/AKT/mTOR pathway[J]. Journal of Practical Oncology, 2019, 33(5): 451-455.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.05.013

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I5/451

参考文献

1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2 Bongiovanni D,Saccomani V,Piovan E.Aberrant signaling pathways in T-cell acute lymphoblastic leukemia[J].Int J Mol Sci,2017,18(9):1904.
3 Senthilkumar R,Chen BA,Cai XH,et al.Anticancer and multidrug-resistance reversing potential of traditional medicinal plants and their bioactive compounds in leukemia cell lines[J].Chin J Nat Med,2014,12(12):881-894.
4 Aoki M,Fujishita T.Oncogenic roles of the PI3K/AKT/mTOR axis[J].Curr Top Microbiol Immunol,2017,407:153-189.
5 Juntilla M,Patil V,Calamito M,et al.AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species[J].Blood,2010,115(20):4030-4038.
6 Montaño A,Forero-Castro M,Marchena-Mendoza D,et al.New challenges in targeting signaling pathways in acute lymphoblastic leukemia by NGS approaches:An Update[J].Cancers,2018,10(4):110.
7 Milella M,Falcone I,Conciatori F,et al.PTEN:Multiple functions in human malignant tumors[J].Front Oncol,2015,5:24.
8 Palomero T,Sulis ML,Cortina M,et al.Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia[J].Nat Med,2007,13(10):1203-1210.
9 Silva A,Yunes JA,Cardoso BA,et al.PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability[J].J Clin Invest,2008,118(11):3762-3774.
10 Subramaniam P,Whye D,Efimenko E,et al.Targeting nonclassical oncogenes for therapy in T-ALL[J].Cancer Cell,2012,21(4):459.
11 Seshacharyulu P,Pandey P,Datta K,et al.Phosphatase:PP2A structural importance,regulation and its aberrant expression in cancer[J].Cancer Lett,2013,335(1):9.
12 Hoshii T,Kasada A,Hatakeyama T,et al.Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells[J].Proc Natl Acad Sci U S A,2014,111(10):3805.
13 Bressanin D,Evangelisti C,Ricci F,et al.Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia:Eliminating activity by targeting at different levels[J].Oncotarget,2012,3(8):811-823.
14 Chiarini F,Falà F,Tazzari PL,et al.Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia[J].Cancer Res,2009,69(69):3520-3528.
15 Lonetti A,Antunes IL,Chiarini F,et al.Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia[J].Leukemia,2013,28(6):1196-1206.
16 Bendell JC,Rodon J,Burris HA,et al.Phase I,dose-escalation study of BKM120,an oral pan-Class I PI3K inhibitor,in patients with advanced solid tumors[J].J Clin Oncol,2012,30(3):282-290.
17 Fan QW,Knight ZA,Goldenberg DD,et al.A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma[J].Cancer Cell,2006,9(5):341.
18 Chiarini F,Sole MD,Mongiorgi S,et al.The novel Akt inhibitor,perifosine,induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism[J].Leukemia,2008,22(6):1106-1116.
19 Nyåkern M,Cappellini A,Mantovani I,et al.Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways[J].Mol Cancer Ther,2006,5(6):1559-1570.
20 Falà F,Blalock WL,Tazzari PL,et al.Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor(2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine(A443654)in T-cell acute lymphoblastic leukemia[J].Mol Pharmacol,2008,74(3):884-895.
21 Cecchinato V,Chiaramonte R,Nizzardo M,et al.Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells[J].Biochem Pharmacol,2007,74(11):1568-1574.
22 Hussain AR,Al-Rasheed M,Manogaran PS,et al.Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias[J].Apoptosis,2006,11(2):245-254.
23 Querfeld C,Rizvi MA,Kuzel TM,et al.The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway[J].J Invest Dermatol,2006,126(7):1641.
24 Avellino R,Romano S,Parasole R,et al.Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells[J].Blood,2005,106(4):1400.
25 Wu KN,Zhao YM,He Y,et al.Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signalin[J].Leuk Lymphoma,2013,55(3):668-676.
26 Batista A,Barata JT,Raderschall E,et al.Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors[J].Exp Hematol,2011,39(4):457-472.
27 Pikman Y,Alexe G,Roti G,et al.Synergistic drug combinations with a CDK4/6 Inhibitor in T-cell acute lymphoblastic leukemia[J].Clin Cancer Res,2017,23(4):1012.
28 Daver N,Boumber Y,Kantarjian H,et al.A phase I/II study of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia[J].Clin Cancer Res,2015,21(12):2704.
29 Rizzieri DA,Feldman E,Dipersio JF,et al.A phase 2 clinical trial of deforolimus(AP23573,MK-8669),a novel mammalian target of rapamycin inhibitor,in patients with relapsed or refractory hematologic malignancies[J].Clin Cancer Res,2008,14(9):2756.
30 Efeyan A,Sabatini DM.mTOR and cancer:many loops in one pathway[J].Curr Opin Cell Biol,2010,22(2):169.
31 Bertacchini J,Guida M,Accordi B,et al.Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis[J].Leukemia,2014,28(11):2197-2205.
32 Kang SA,Pacold ME,Cervantes CL,et al.mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin[J].Science,2013,341(6144):1236566.
33 Chiarini F,Grimaldi C,Ricci F,et al.Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia[J].Cancer Res,2010,70(20):8097.
34 Avellino R,Romano S,Parasole R,et al.Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells[J].Blood,2005,106(4):1400.
35 Chan SM,Weng AP,Tibshirani R,et al.Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia[J].Blood,2007,110(1):278-286.
36 Evangelisti C,Ricci F,Tazzari P,et al.Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia[J].Leukemia,2011,25(5):781.
37 Place AE,Pikman Y,Stevenson KE,et al.Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia[J].Pediatr Blood Cancer,2018,65(7):e27062.
38 Park S,Chapuis N,Saint MF,et al.A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse[J].Leukemia,2013,27(7):1479-1486.
39 Gentzler DRD,Altman DJK,Platanias DLC.An overview of the mTOR pathway as a target in cancer therapy[J].Expert Opin Ther Targets,2012,16(5):481-489.
40Willems L,Chapuis N,Puissant A,et al.The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia[J].Leukemia,2012,26(6):1195-1202.
41 Gupta M,Hendrickson AE,Yun SS,et al.Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies[J].Blood,2012,119(2):476.

[1]	池淑琦综述, 汪宏波审校. 长链非编码RNA与肿瘤耐药性的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 150-153.
[2]	马瑞金综述杨宇审校. PI3K/AKT/mTOR 信号通路在乳腺癌HER2治疗耐药中的作用研究进展[J]. 实用肿瘤学杂志, 2014, 28(4): 360-363.